Literature DB >> 881094

Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena.

E F Ring, P A Bacon.   

Abstract

The basal temperature of the hands has been measured by quantitative thermography in a group of normal controls and rheumatoid patients exhibiting Raynaud's phenomenon. The thermographic index for both the dorsum of the hand and the fingers was significantly lower in the patients with Raynaud's. Oral treatment with inositol nicotinate (Hexopal) was followed by an initial rise in the thermographic index in both areas. After the initial increase the temperature fell again but then rose after two months treatment. At nine months two subjects on continuous therapy had higher indices than the four who had discontinued therapy. It is suggested that long-term treatment with nicotinate acid derivatives may produce improvement in the peripheral circulation by a different mechanism than the transient effect detected by short-term studies.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 881094     DOI: 10.1177/030006057700500401

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

Review 1.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

2.  A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.

Authors:  G T Sunderland; J J Belch; R D Sturrock; C D Forbes; A J McKay
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

3.  Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.

Authors:  J J Belch; J Cormie; P Newman; M McLaren; J Barbenel; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 4.  The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Thais Ribeiro Peclat; Bo Shi; John Varga; Eduardo Nunes Chini
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.